This phase II trial studies how well donor cytotoxic T lymphocytes work in treating patients with malignancies with BK and/or JC virus. Cytotoxic T lymphocytes are made from donated blood cells that are grown in the laboratory and are designed to kill viruses that can cause infections in transplant patients and may be an effective treatment in patients with malignancies with BK and/or JC virus.
Patients ≥ 2 years.
English and non-English speaking patients are eligible.
Immunocompromised patients including but not limited to those with any type of malignancy, HIV/AIDS, or history of solid organ transplant
Non-immunocompromised patients with PML/JC virus encephalitis
Patients receiving > 6 mg / day of prednisone or equivalent at time of
Patients who have received ATG within 14 days of enrollment
Patients who have received donor lymphocyte infusion (DLI) within 28 days of enrollment.
Patients who have received alemtuzumab within 28 days of enrollment.
M.D. Anderson Cancer Center
Lead sponsor
National Cancer Institute (NCI)
Collaborator